Puff Puff Post

MARCH 10, 2020

“We are very pleased with the rapid completion of enrollment achieved by the team at the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands,” said Alexandra Mancini, InMed’s Senior Vice President of Clinical Development & Regulatory Affairs.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Veriheal

NOVEMBER 17, 2020

Ohio is currently accepting petitions in an attempt to expand the list of qualifying conditions for medical cannabis. But this has failed in the past and could prevent measures from moving forward this time unless new research could be presented to sway the state medical board’s decision.

Conditions 98

Conditions Research and Development Pharmaceutical Clinical Trials 98

FloridaMarijuana.net

AUGUST 15, 2018

If this mechanism is forced to be used repeatedly and often, the body does not properly heal or develop. Often, Post-Traumatic Stress Disorder, a debilitating and chronic illness, can develop. About 10 of every 100 women (or 10%) develop PTSD sometime in their lives compared with about 4 of every 100 men (or 4%).

Treatment 182

Treatment Marijuana Research and Development Therapy 182

MMJ Recs

MAY 9, 2024

Many veterans struggle with various physical and psychological conditions resulting from their service. In this instance, medical cannabis offers a promising alternative or complementary treatment option. These centers often cater to individuals seeking natural and non-traditional treatment options.

Research and Development 52

Research and Development Therapy Clinical Trials Treatment 52

Puff Puff Post

JANUARY 1, 2020

As cannabis legalisation spreads, research has found considerable use in for cannabis in medicine. One particularly promising area of research is in the treatment of cancer. Cancer patients suffer not only from cancer, but the damaging effects of treatment. Cannabis Cancer Treatments as an Alternative to Opioids.

Treatment 64

Treatment Clinical Trials Research and Development Cannabinoids 64

Veriheal

JULY 16, 2020

The commission tasked with developing recommendations to improve mental health treatment for veterans concluded: Congress and the executive branch need to promote research into the therapeutic potential of cannabis and psychedelics such as psilocybin mushrooms and MDMA. Research is Limited Due to Many Obstacles.

Research and Development 95

Research and Development Clinical Trials Treatment Compliance 95

Cannabis Law Report

OCTOBER 15, 2021

(USOTC: PAOG) cited a British Medical Journal case study report published today on the effectiveness of CBD in the treatment of lung cancer and COPD as validation of PAOG’s ongoing research and development of its own respiratory disorder treatment under the name RespRx. 9,199,960).

Treatment 52

Treatment Research and Development CBD eCommerce 52

LifeCannMD

FEBRUARY 27, 2024

Medical Marijuana exhibits neuroprotective properties, meaning it can protect nerve cells against damage, degeneration, or impairment of function in conditions like epilepsy, where excessive neuronal activity can lead to damage. Inflammation in the brain is thought to contribute to the development and persistence of seizures.

Clinical Trials 59

Clinical Trials Epilepsy Marijuana Research and Development 59

MMJ Recs

NOVEMBER 20, 2023

These two cannabinoids represent just a fraction of the compounds within the cannabis plant, and ongoing research continues to uncover the potential of other lesser-known cannabinoids. Additionally, they may help slow the growth of certain types of cancer cells, though further research is needed.

Cannabinoids 98

Cannabinoids Epilepsy Treatment Marijuana 98

Cannabis Law Report

JUNE 30, 2021

Yet, despite nearly two billion people with mental illness each year, these conditions are routinely misdiagnosed and inadequately treated. In addition, the company aims to predict what treatments are most effective in addressing these conditions, including psychedelics, which have shown tremendous promise in early clinical trials.

Treatment 52

Treatment Clinical Trials Research and Development Data 52

Puff Puff Post

JANUARY 1, 2020

As cannabis legalisation spreads, research has found considerable use in for cannabis in medicine. One particularly promising area of research is in the treatment of cancer. Cancer patients suffer not only from cancer, but the damaging effects of treatment. Cannabis Cancer Treatments as an Alternative to Opioids.

Treatment 40

Treatment Clinical Trials Research and Development Cannabinoids 40

Veriheal

FEBRUARY 9, 2023

Although many rely on imaging scans to diagnose illnesses and get treatment of various kinds, getting into the enclosed chamber can be stressful. Now, Australian researchers think they may have found an answer: taking psilocybin before MRIs. There is still much yet to learn about how psilocybin can work in a clinical setting.

Clinical Trials 98

Clinical Trials Research and Development Data Collective 98

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma’s objective is to create and leverage a proprietary drug development platform in collaboration with an artificial intelligence and machine learning group to identify new bioactive compounds within the cannabis plant that interact with certain gene targets responsible for specific disease states and conditions.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Cannabis Law Report

AUGUST 26, 2022

Several companies are facilitating the development of this product. More research is still needed to explore this uncharted territory. CBD has been suggested to act as a treatment for sclerosis symptoms, as well as epilepsy among children. However, deeper research is needed to better understand its roles. billion in 2021.

Epilepsy 52

Epilepsy Treatment CBD Sleep 52

Cannabis Law Report

JULY 27, 2021

.–(BUSINESS WIRE)– Realm of Caring (RoC) , a nonprofit dedicated to cannabinoid research, has appointed Nicolas Schlienz, Ph.D., as its Research Director, a new role in the organization’s leadership. It is our hope that this study may embolden clinicians and patients to effectively partner in considering these treatments.”.

Data 105

Data Epilepsy Research and Development Clinical Trials 105

Cannabis Law Report

MAY 29, 2022

Earlier this month, Senators Brian Schatz (D-HI) and Cory Booker (D-NJ) sent a letter to the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) urging both agencies to advance research on the therapeutic effects of psychedelic drugs. [1] Recent Regulatory Developments. Challenges.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Puff Puff Post

MARCH 10, 2020

“We are very pleased with the rapid completion of enrollment achieved by the team at the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands,” said Alexandra Mancini, InMed’s Senior Vice President of Clinical Development & Regulatory Affairs.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

AUGUST 22, 2021

Silo Pharma’s notice of allowance paves the way toward clinical trials for its psychedelics delivery platform using homing peptides. OTCQB: SILO), a development-stage biopharmaceutical company focused on the therapeutic potential of psychedelics, recently announced that the U.S. Silo Pharma Inc. Looking to the Future.

Clinical Trials 105

Clinical Trials Research and Development Safety Treatment 105

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. The cannabis research problem. Despite the massive amount of research publications that come out year over year, many of these studies face one or more research design limitations.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Cannabis Law Report

DECEMBER 26, 2021

The patent relates to improved technology for detection and maintenance of the optimal therapeutic psychedelic state, which Entheon intends to study through the monitoring of electroencephalogram (EEG) biomarkers in order to optimize the treatment of neuropsychiatric conditions. ” In Vivo Toxicity Assays Completed.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Veriheal

APRIL 11, 2022

federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field of cannabis-based medicine,” reads an official statement from the company’s website.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

DECEMBER 21, 2021

CBG or cannabigerol is obtained from immature cannabis plants since it is not present in fully developed plants. In most fully developed cannabis plants with considerable THC and CBD concentrations, CBG levels are relatively low. Research has proven that CBG has many therapeutic qualities. Huntington’s disease.

Conditions 52

Conditions Research and Development Clinical Trials Oil 52

Cannabis Law Report

JUNE 19, 2022

Partnership will focus on the collection and analysis of digital biomarkers to identify signs of response and relapse in upcoming Phase 2 clinical trials. Beckley Psytech aims to track and improve patient experience through an integrated, digitally-assisted treatment model. June 14, 2022 02:00 AM Eastern Daylight Time.

Clinical Trials 52

Clinical Trials Patients Research and Development Treatment 52

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ International Holdings is developing oral drug products from natural whole plant extract derivatives from the marijuana plant containing THC and CBD. Orphan Drug Designation?

DEA 66

DEA Clinical Trials THC Research and Development 66

SpeedWeed

AUGUST 16, 2021

Oxford-based startup Beckley Psytech in the United Kingdom announced August 15 that it raised $80 million to ramp up clinical trials and research using a pharmaceutical formulation of ??5-MeO-DMT Clinical studies using psilocybin show huge potential to battle treatment-resistant depression, under the guidance of a therapist.

Research and Development 52

Research and Development Clinical Trials Treatment Conditions 52

Cannabis Law Report

JULY 25, 2022

together with research collaborators at the University of Auckland , have received NZ$1.44 million ($650,000) in funding from New Zealand’s Health Research Council (HRC) to conduct a LSD microdosing trial in patients with Major Depressive Disorder (MDD). — MindBio Therapeutics (@MindBioTherap) July 10, 2022.

Microdosing 52

Microdosing Clinical Trials Research and Development Data 52

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood. About MyMD Pharmaceuticals, Inc.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Cannabis Law Report

AUGUST 2, 2021

capital markets, negative global economic conditions, potential negative developments in our clinical trials or research programs, other negative developments in our business, or unfavorable legislative or regulatory developments. About Bionomics Limited.

Clinical Trials 105

Clinical Trials Research and Development Treatment Conditions 105

Cannabis Law Report

MAY 12, 2022

Beckley Psytech to collaborate with Lophora on researching New Clinical Entities (NCE’s). Under the terms of the agreement Beckley Psytech will jointly fund continuing development of the Lophora pipeline and collaborate broadly on R&D. May 11, 2022 02:00 AM Eastern Daylight Time.

Medicine 52

Medicine Research and Development Clinical Trials Treatment 52

Puff Puff Post

JANUARY 13, 2020

Now that retailers broadly sell CBD oil, it offers a number of challenges and opportunities to medical researchers. Preliminary Research on CBD Oil. Pharmacies, as more profitable companies, have the resources to research the other cannabinoids present in CBD oil. Cannabidiol As Treatment For Opiate and Alcohol Addiction.

CBD 52

CBD Clinical Trials Research and Development Oil 52

Puff Puff Post

JANUARY 13, 2020

Now that retailers broadly sell CBD oil, it offers a number of challenges and opportunities to medical researchers. Preliminary Research on CBD Oil. Pharmacies, as more profitable companies, have the resources to research the other cannabinoids present in CBD oil. Cannabidiol As Treatment For Opiate and Alcohol Addiction.

CBD 52

CBD Clinical Trials Research and Development Oil 52

Cannabis Law Report

SEPTEMBER 2, 2021

The use of cannabinoids in the treatment of medical conditions offers major opportunities and challenges to anyone operating in the space. Prohibition Partners has identified at least 30 late-stage clinical trials using cannabinoid therapeutics, any of which will probably have a large impact on the medicinal cannabis space.

Pharmaceutical 105

Pharmaceutical Clinical Trials Research and Development Cannabinoids 105

Cannabis Law Report

MARCH 25, 2020

OTCQB: AXIM) (“AXIM® Biotech” or “AXIM”) has completed the acquisition of leading oncology research and development company Sapphire Biotech, Inc. (“Sapphire”). Valencia has stewarded Sapphire in the development of its unique patent-pending pipeline. CEO Dr. Stuart Titus.

Research and Development 59

Research and Development Supply Chain Pharmaceutical Clinical Trials 59

Veriheal

MAY 3, 2022

A recent study , funded by the National Institute on Drug Abuse (NIDA) and published in JAMA Network Open , reported a correlation between obtaining a medical marijuana (MMJ) card and developing CUD. Despite being published in a reputable journal, there are questions about the legitimacy of the research. Clinical Trial Sample Size.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98

Cannabis Law Report

MAY 28, 2022

The firm represents clients around the world in major industries including energy and natural resources; financial services and capital markets; food and agribusiness; healthcare, life sciences and education; real estate, development and construction; and technology, manufacturing and transportation. How did this come to fruition?

Research and Development 52

Research and Development Therapy Clinical Trials Legalization 52

Cannabis Law Report

AUGUST 5, 2021

Psychedelics are quickly emerging as alternative methods of treatment for mental illnesses and neurodegenerative conditions — particularly in countries such as Canada. What’s more, over the coming years psychedelics will continue to gain acceptance for treating these conditions which will also contribute to that market growth.

Extraction 105

Extraction Clinical Trials Research and Development Pharmaceutical 105

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., at the end of the 17 weeks of ganaxolone treatment.

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52